Exogenous gonadotropin therapy in combined anovulatory and male factor infertility.
This retrospective study evaluated conception rates in 18 women with refractory anovulatory infertility undergoing hMG ovulation induction in the presence of persistent mild to moderate semen abnormalities. Logistic regression analysis showed no relationship between conception (9.6% cycle) and the age of either partner, primary versus secondary infertility, or lowest sperm count, motility or morphology. In summary, this study demonstrates that a coexisting mild to moderate male factor does not preclude pregnancy during hMG therapy for anovulation. While semen abnormalities should not be ignored, aggressive treatment of concomitant ovulatory disorders and the resulting timed ovulation of several oocytes may minimize the effects of semen abnormalities.
Fluker
M R
MR
Department of Obstetrics and Gynecology University of British Columbia Vancouver, Canada.
Fleige-Zahradka
B G
BG
Yuen
B H
BH
D000328:Adult; D000858:Anovulation / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005306:Fertilization; D006801:Humans; D007248:Infertility, Male / Q000150:complications*; D008297:Male; D008596:Menotropins / Q000627:therapeutic use*; D009845:Oligospermia / Q000150:complications; D010062:Ovulation Induction / Q000379:methods; D011247:Pregnancy; D011256:Pregnancy Outcome; D012189:Retrospective Studies; D013081:Sperm Motility; D013094:Spermatozoa / Q000002:abnormalities
D008596:Menotropins